BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 13/04/2011

FDA Clears NOVANTRONE Injection for Sale, Citing Lack of Safety or Effectiveness Concerns

The US Food and Drug Administration (FDA) has announced that NOVANTRONE (mitoxantrone hydrochloride) Injection, available in two different strengths, will not be withdrawn from sale due to concerns over its safety or effectiveness, allowing the FDA to continue approving abbreviated new drug applications (ANDAs) for the product.

Source: Federal Register — Health and Human ServicesOpen original release →